NCT04003623

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumors Harboring Activating FGFR Mutations or Translocations (FIGHT-208)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumors harboring activating FGFR mutations or translocations.

Conditions

• Advanced or Metastatic Solid Tumors
• FGFR Mutations
• FGFR Translocations

Interventions

Type	Name	Description
DRUG	Pemigatinib	Pemigatinib administered orally once daily.

Timeline

• Start date: 2019-10-31
• Primary completion: 2020-06-12
• Completion: 2020-06-12
• First posted: 2019-07-01
• Last updated: 2022-05-10
• Results posted: 2022-04-21

Locations

11 sites across 1 country: United States

Regulatory

• FDA-regulated drug study